- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03893292
Preop Cooled Radiofrequency Ablation for Total Knee Replacement
November 10, 2020 updated by: Hospital for Special Surgery, New York
A Pilot Study on the Utility of Cooled Radiofrequency Ablation in Patients Prior to Total Knee Arthroplasty
Total knee replacement surgery is commonly performed for patients suffering from severe knee osteoarthritis.
However, 20% of patients continue to experience pain after surgery.
There is currently no standardized pain management protocol for pain after total knee replacement.
Cooled radiofrequency ablation has been used successfully to alleviate spin-related pain and has recently been approved by the FDA to treat chronic knee arthritic pain.
This pilot study aims to collect preliminary data on the use of cooled radiofrequency ablation in patients undergoing total knee replacement.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
The number of patients who undergo total knee replacement is rising significantly.
However, many of these patients are dissatisfied with the results, because they continue to experience pain postoperatively.
This pain can be debilitating and can also be associated with decreased quality of life.
Given the increasing number of patients undergoing total knee replacement and a dissatisfaction rate of 8-44%, improvements must be made in pain management protocols to help decrease pain in the immediate postoperative period following total knee replacement.
Cooled radiofrequency ablation is a procedure that uses water-cooled technology to denervate the sensory nerves.
It is widely used in the spine and is increasingly being used in the knee to treat osteoarthritis.
Existing studies have shown that it can significantly reduce pain in patients with chronic osteoarthritis.
In terms of its potential benefit as a preoperative measure to minimize postoperative pain, the literature is sparse.
Results from this study will be used to generate hypotheses and power for future studies.
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Hospital for Special Surgery
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients undergoing unilateral primary total knee replacement for the treatment of knee osteoarthritis
Description
Inclusion Criteria:
- Patients undergoing unilateral primary total knee replacement for osteoarthritis
- Pain >6 (on a scale of 0-10)
- Body mass index: 21-35 kg/m2
Exclusion Criteria:
- Age <65 years
- Patients who are wheelchair bound
- History of inflammatory arthritis or rheumatic disease
- Body mass index <21 or >35 kg/m2
- Chronic opioid use
- Pregnant women
- Non-English speaking
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Preoperative cooled radiofrequency ablation
Patients who undergo cooled radiofrequency ablation within 4-8 weeks of their scheduled total knee replacement.
|
Patients will undergo total knee replacement surgery.
The superior lateral genicular nerve, superior medial genicular nerve, and inferior medial geniculate nerve will be ablated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain
Time Frame: Up to 1 year post-total knee replacement
|
Pain will be assessing on a 0-10 scale, where 0=no pain and 10=most pain.
|
Up to 1 year post-total knee replacement
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knee Disability
Time Frame: Up to 1 year post-total knee replacement
|
Knee disability will be assessed using the Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR).
The score ranges from 0-100, where 0=total knee disability and 10=perfect health.
|
Up to 1 year post-total knee replacement
|
|
Function assessed using the PROMIS-physical function computer adaptive test
Time Frame: Up to 1 year post-total knee replacement
|
Function will be assessed using the PROMIS-physical function computer adaptive test.
A higher score indicates higher function.
|
Up to 1 year post-total knee replacement
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jonathan Kirschner, MD, Hospital for Special Surgery, New York
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 24, 2019
Primary Completion (Actual)
October 30, 2020
Study Completion (Actual)
October 30, 2020
Study Registration Dates
First Submitted
March 26, 2019
First Submitted That Met QC Criteria
March 27, 2019
First Posted (Actual)
March 28, 2019
Study Record Updates
Last Update Posted (Actual)
November 13, 2020
Last Update Submitted That Met QC Criteria
November 10, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-1149
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.